CytomX Therapeutics, Inc.
CTMXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The $788.1M market capitalization puts CTMX squarely in small-cap range for its industry. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Market Cap
$788.1M
Beta
2.08
P/E (TTM)
—
P/E (Fwd)
-7.45
EPS (TTM)
$-0.52
EPS (Fwd)
$-0.49
ROE
-34.3%
ROA
-16.9%
Cash
$346.7M
Total Debt
$2.9M
Free CF
-$41.9M
52W Change
51.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $346.7M in cash comfortably exceeding the $2.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$41.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -34.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $53.2M (2022) to $76.2M (2025), reflecting a 43% increase over the period.
A beta of 2.08 means CTMX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CytomX Therapeutics, Inc. and its sector.